search
Back to results

Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus

Primary Purpose

Obesity; Endocrine; Diabetes Type 2

Status
Completed
Phase
Early Phase 1
Locations
Egypt
Study Type
Interventional
Intervention
Montelukast 10mg
Placebo
Sponsored by
Sadat City University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity; Endocrine; Diabetes Type 2

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

- type 2 diabetic patients who had body mass index (BMI) ≥ 30 kg/m2 , were treated with metformin alone and had ages ranging from 18 to 60 years.

Exclusion Criteria:

  • patients who had any other inflammatory disease
  • patients with cardiovascular,
  • patients with asthma
  • patients with severe hepatic
  • patients with renal disease,
  • patients with epilepsy
  • pregnant or lactating females.

Sites / Locations

  • Faculty of Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Control group

Montelukast group

Arm Description

50 patients will receive metformin up to 2000mg/daily (Control group)

50 patients will receive a combination of metformin up to 2000 mg/daily and montelukast (10 mg /day).

Outcomes

Primary Outcome Measures

Change in HbA1c
HbA1c
Percent change in body weight
Body Weight
BMI
body mass index
Visceral Adiposity Index
visceral fat

Secondary Outcome Measures

Adiponectin
Serum level of adiponectin
TNF-α
Serum level of Tumor necrosis factor alpha (TNF-α)
IL-6
Serum level of interleukin-6 (IL-6)
leukotriene B4
Serum level of leukotriene B4 (LTB4)

Full Information

First Posted
August 28, 2019
Last Updated
April 10, 2023
Sponsor
Sadat City University
search

1. Study Identification

Unique Protocol Identification Number
NCT04075110
Brief Title
Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus
Official Title
Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus: A Randomized, Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
July 1, 2019 (Actual)
Primary Completion Date
June 1, 2022 (Actual)
Study Completion Date
April 10, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sadat City University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of the current study is to evaluate the safety and efficacy of Montelukast in treatment of obese patients with type 2 diabetes (T2DM).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity; Endocrine; Diabetes Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control group
Arm Type
Placebo Comparator
Arm Description
50 patients will receive metformin up to 2000mg/daily (Control group)
Arm Title
Montelukast group
Arm Type
Experimental
Arm Description
50 patients will receive a combination of metformin up to 2000 mg/daily and montelukast (10 mg /day).
Intervention Type
Drug
Intervention Name(s)
Montelukast 10mg
Intervention Description
Montelukast is an orally dosed drug (available as a chewable tablet) which is FDA-approved for the treatment of chronic asthma and prophylaxis and the prevention of exercise-induced bronchoconstriction. It is also approved for the relief of symptoms of both seasonal and perennial allergic rhinitis.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo tablet once daily
Primary Outcome Measure Information:
Title
Change in HbA1c
Description
HbA1c
Time Frame
From baseline to 12 weeks
Title
Percent change in body weight
Description
Body Weight
Time Frame
From baseline to 12 weeks
Title
BMI
Description
body mass index
Time Frame
From baseline to 12 weeks
Title
Visceral Adiposity Index
Description
visceral fat
Time Frame
From baseline to 12 weeks
Secondary Outcome Measure Information:
Title
Adiponectin
Description
Serum level of adiponectin
Time Frame
At baseline to 12 weeks
Title
TNF-α
Description
Serum level of Tumor necrosis factor alpha (TNF-α)
Time Frame
At baseline to 12 weeks
Title
IL-6
Description
Serum level of interleukin-6 (IL-6)
Time Frame
At baseline to 12 weeks
Title
leukotriene B4
Description
Serum level of leukotriene B4 (LTB4)
Time Frame
At baseline to 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - type 2 diabetic patients who had body mass index (BMI) ≥ 30 kg/m2 , were treated with metformin alone and had ages ranging from 18 to 60 years. Exclusion Criteria: patients who had any other inflammatory disease patients with cardiovascular, patients with asthma patients with severe hepatic patients with renal disease, patients with epilepsy pregnant or lactating females.
Facility Information:
Facility Name
Faculty of Medicine
City
Shebin Elkom
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
Yes

Learn more about this trial

Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus

We'll reach out to this number within 24 hrs